JP6998087B2 - 第一鉄アミノ酸粒子を含む組成物、およびその組成物を含む、膵臓関連疾患の治療または改善のための薬剤 - Google Patents
第一鉄アミノ酸粒子を含む組成物、およびその組成物を含む、膵臓関連疾患の治療または改善のための薬剤 Download PDFInfo
- Publication number
- JP6998087B2 JP6998087B2 JP2020540748A JP2020540748A JP6998087B2 JP 6998087 B2 JP6998087 B2 JP 6998087B2 JP 2020540748 A JP2020540748 A JP 2020540748A JP 2020540748 A JP2020540748 A JP 2020540748A JP 6998087 B2 JP6998087 B2 JP 6998087B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pancreatic cancer
- gemcitabine
- present
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
より好ましくは、前記経腸投薬形態は経口投薬形態である。前記経口剤形は、溶液、乳濁液、懸濁液、粉末、錠剤、ピル、ロゼンジ、トローチ、チューインガム、またはカプセルである。
Claims (8)
- 第一鉄アミノ酸キレートから焼結された第一鉄アミノ酸キレート粒子を含む組成物であって、第一鉄アミノ酸キレート粒子の平均粒子サイズが500nmから2600nmの範囲であり、平均分子量が1,500ダルトンから600,000ダルトンの範囲である、組成物。
- 前記組成物中の第一鉄アミノ酸キレートのアミノ酸に対する、第一鉄のキレート化比が1:1と1:4の間である、請求項1記載の組成物。
- 第一鉄アミノキレートがグリシン酸第一鉄キレートである、請求項1記載の組成物。
- 膵臓癌から産生された腹水を低減または改善し、膵臓癌、膵臓癌の転移、及び膵炎を治療または改善するための薬剤であって、有効量の、請求項1から3のいずれかに記載の組成物と、薬学的に許容可能な担体とを含む薬剤。
- 前記組成物がヒトに投与されるものである、請求項4記載の薬剤。
- 有効量が0.1mg/kg/日から120mg/kg/日の範囲である、請求項4に記載の薬剤。
- 前記組成物がゲムシタビンと共に投与されるものである、請求項4記載の薬剤。
- ゲムシタビンが、一以上のゲムシタビンサイクルを含む用法・用量で投与され、各ゲムシタビンサイクルは、ゲムシタビンを週2回、3週間投与し、4週目にゲムシタビンを中止することから構成される、請求項7に記載の薬剤。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/122406 WO2020124495A1 (zh) | 2018-12-20 | 2018-12-20 | 含有亚铁氨基酸粒子的组合物及其用于制造治疗或改善胰脏相关疾病的医药品的用途 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021511358A JP2021511358A (ja) | 2021-05-06 |
JP2021511358A5 JP2021511358A5 (ja) | 2021-06-17 |
JP6998087B2 true JP6998087B2 (ja) | 2022-02-04 |
Family
ID=71101000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020540748A Active JP6998087B2 (ja) | 2018-12-20 | 2018-12-20 | 第一鉄アミノ酸粒子を含む組成物、およびその組成物を含む、膵臓関連疾患の治療または改善のための薬剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220031651A1 (ja) |
EP (1) | EP3900719A4 (ja) |
JP (1) | JP6998087B2 (ja) |
CN (1) | CN111655252B (ja) |
AU (1) | AU2018454589A1 (ja) |
CA (1) | CA3087911A1 (ja) |
WO (1) | WO2020124495A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114767710B (zh) * | 2022-04-12 | 2023-07-07 | 中山大学 | 甘氨酸亚铁在治疗类风湿关节炎中的应用 |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002030947A3 (en) | 2000-10-11 | 2002-07-25 | Albion Int | Compositions and methods of preparing amino acid chelates and complexes |
JP2008525442A (ja) | 2004-12-22 | 2008-07-17 | ドラッグテック コーポレイション | 鉄を含む組成物 |
JP2009523826A (ja) | 2006-01-18 | 2009-06-25 | アルビオン アドバンスト ニュートリション | 溶解性が改善された混合されたアミノ酸/鉱物化合物 |
US20150065569A1 (en) | 2013-09-05 | 2015-03-05 | Profeat Biotechnology Co., Ltd. | Method for cancer treatment |
JP2016510006A (ja) | 2013-09-05 | 2016-04-04 | 普惠徳生技股▲ふん▼有限公司 | 癌治療のための使用 |
JP2019519603A (ja) | 2016-05-26 | 2019-07-11 | 普惠▲徳▼生技股▲分▼有限公司 | 乳酸を減少させるために使用する第一鉄アミノ酸キレートを含む組成物 |
US20190274967A1 (en) | 2018-03-06 | 2019-09-12 | Profeat Biotechnology Co., Ltd. | Sintered ferrous amino acid particles and use of the same against a virus |
US20190314322A1 (en) | 2018-04-13 | 2019-10-17 | Profeat Biotechnology Co., Ltd. | Use of ferrous amino acid chelate to treat infection by enteropathogen and to enhance growth performance |
JP2019536789A (ja) | 2016-12-02 | 2019-12-19 | 普惠徳生技股▲ふん▼有限公司 | アミノ酸第一鉄キレート含有組成物を含むがん転移を抑制するための医薬 |
US20200138726A1 (en) | 2018-03-06 | 2020-05-07 | Profeat Biotechnology Co., Ltd. | Sintered nanoparticles and use of the same against a virus |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108371668B (zh) * | 2018-02-25 | 2020-11-24 | 四川大学 | 具有抗肿瘤作用的纳米羟基磷灰石粒子及制备方法和用途 |
-
2018
- 2018-12-20 US US16/965,181 patent/US20220031651A1/en active Pending
- 2018-12-20 CN CN201880086420.2A patent/CN111655252B/zh not_active Expired - Fee Related
- 2018-12-20 CA CA3087911A patent/CA3087911A1/en not_active Abandoned
- 2018-12-20 EP EP18943815.3A patent/EP3900719A4/en not_active Withdrawn
- 2018-12-20 AU AU2018454589A patent/AU2018454589A1/en not_active Abandoned
- 2018-12-20 JP JP2020540748A patent/JP6998087B2/ja active Active
- 2018-12-20 WO PCT/CN2018/122406 patent/WO2020124495A1/zh unknown
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002030947A3 (en) | 2000-10-11 | 2002-07-25 | Albion Int | Compositions and methods of preparing amino acid chelates and complexes |
JP2008525442A (ja) | 2004-12-22 | 2008-07-17 | ドラッグテック コーポレイション | 鉄を含む組成物 |
JP2009523826A (ja) | 2006-01-18 | 2009-06-25 | アルビオン アドバンスト ニュートリション | 溶解性が改善された混合されたアミノ酸/鉱物化合物 |
US20150065569A1 (en) | 2013-09-05 | 2015-03-05 | Profeat Biotechnology Co., Ltd. | Method for cancer treatment |
JP2016510006A (ja) | 2013-09-05 | 2016-04-04 | 普惠徳生技股▲ふん▼有限公司 | 癌治療のための使用 |
JP2019519603A (ja) | 2016-05-26 | 2019-07-11 | 普惠▲徳▼生技股▲分▼有限公司 | 乳酸を減少させるために使用する第一鉄アミノ酸キレートを含む組成物 |
JP2019536789A (ja) | 2016-12-02 | 2019-12-19 | 普惠徳生技股▲ふん▼有限公司 | アミノ酸第一鉄キレート含有組成物を含むがん転移を抑制するための医薬 |
US20190274967A1 (en) | 2018-03-06 | 2019-09-12 | Profeat Biotechnology Co., Ltd. | Sintered ferrous amino acid particles and use of the same against a virus |
US20190358168A1 (en) | 2018-03-06 | 2019-11-28 | Profeat Biotechnology Co., Ltd. | Sintered ferrous amino acid particles and use of the same against a virus |
US20200138726A1 (en) | 2018-03-06 | 2020-05-07 | Profeat Biotechnology Co., Ltd. | Sintered nanoparticles and use of the same against a virus |
US20190314322A1 (en) | 2018-04-13 | 2019-10-17 | Profeat Biotechnology Co., Ltd. | Use of ferrous amino acid chelate to treat infection by enteropathogen and to enhance growth performance |
Non-Patent Citations (2)
Title |
---|
Nutrition,2001年,17,p.381-384 |
Revista de Nutricao,2008年,21(5),p.483-490 |
Also Published As
Publication number | Publication date |
---|---|
EP3900719A1 (en) | 2021-10-27 |
CA3087911A1 (en) | 2020-06-25 |
WO2020124495A1 (zh) | 2020-06-25 |
AU2018454589A1 (en) | 2020-08-06 |
JP2021511358A (ja) | 2021-05-06 |
CN111655252B (zh) | 2021-08-06 |
US20220031651A1 (en) | 2022-02-03 |
CN111655252A (zh) | 2020-09-11 |
EP3900719A4 (en) | 2022-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Boretti et al. | Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome | |
US11090330B2 (en) | Pharmaceutical solution having a toxicity-reducing effect for antitumor drugs, and pharmaceutical composition comprising same | |
JPWO2008081927A1 (ja) | 抗癌剤の併用による癌治療方法 | |
CN110420329A (zh) | 利用天然化合物和/或饮食调控癌症 | |
CN115006414B (zh) | 人参皂苷Rg3的新用途 | |
JP6998087B2 (ja) | 第一鉄アミノ酸粒子を含む組成物、およびその組成物を含む、膵臓関連疾患の治療または改善のための薬剤 | |
CN107206053A (zh) | 用于治疗血细胞减少症或减少血细胞减少症的持续时间的佛波醇酯组合物和方法 | |
CN105497059B (zh) | 一种石斛提取物与铁的复合物及其制备方法与应用 | |
CN102441168A (zh) | 含芹菜素及芹菜素类衍生物和Bcl-2抑制剂的药物组合物及其在制备治疗癌症的药物中的应用 | |
JP6487531B2 (ja) | 漢方薬毛チコリの脂肪降下有効成分を配合した組成物 | |
CN108295085B (zh) | 原薯蓣皂苷在制备抗耐药性骨肉瘤药物中的应用 | |
TWI695719B (zh) | 含有亞鐵胺基酸粒子的組合物及其用於製造治療或改善胰臟相關疾病的醫藥品的用途 | |
EP3928835A1 (en) | Water-soluble polymeric derivative of venetoclax | |
JP2021511358A5 (ja) | 第一鉄アミノ酸粒子を含む組成物、およびその組成物を含む、膵臓関連疾患の治療または改善のための薬剤 | |
CN112618569A (zh) | 一种用于治疗尿路上皮癌的药物 | |
CN111393278A (zh) | 一种长松萝衍生物及其在制备治疗胆囊癌药物中的用途 | |
CN116687954A (zh) | 一种用于治疗皮肤恶性黑色素瘤的组合物 | |
JP6801908B1 (ja) | ベネトクラクスの水溶性高分子誘導体 | |
AU2011236979B2 (en) | Composition for amelioration of hypoalbuminemia | |
CN110876803A (zh) | 一种包含乳蛋白和油酸的药物组合物 | |
Hossain et al. | Comparative study of efficacy of oral iron versus parenteral iron in the treatment of iron deficiency anaemia | |
JP2002121132A (ja) | 発がん抑制剤および発がん抑制方法 | |
CN110876801A (zh) | GM-CSF与Dencichine联用在制备治疗炎性肠病药物中的用途 | |
CN118576579A (zh) | 二氢咖啡酸在制备预防和/或治疗癌症的药物中的应用 | |
CN116173045A (zh) | 甘油磷脂类化合物在预防和治疗高血脂、动脉粥样硬化、非酒精性脂肪肝和肥胖中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200727 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200727 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210824 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211115 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211207 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211213 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6998087 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |